A new partnership announced in Canberra today offers a glimpse of what the next phase of the obesity drug revolution could look like and the policy debates that will come with it. Novo Nordisk, the Danish pharmaceutical giant behind blockbuster weight-loss drugs like Ozempic and Wegovy, signed a research agreement with the Murdoch Children’s Research Institute to explore new models of care for adolescents living with obesity across Pacific Island nations.